# Large Scale Transition to a Dolutegravir-based First-line ART in the South: Virological Response and Impact on HIV Drug Resistance in a Real Life Context (DoReaL Study)

> **NCT05312918** · — · UNKNOWN · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 603 (estimated)

## Conditions studied

- HIV Infections

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05312918
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05
- **Primary completion:** 2023-03
- **Final completion:** 2024-10
- **Target enrollment:** 603 (ESTIMATED)
- **Last updated:** 2022-04-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05312918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05312918, "Large Scale Transition to a Dolutegravir-based First-line ART in the South: Virological Response and Impact on HIV Drug Resistance in a Real Life Context (DoReaL Study)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05312918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*